Early GI Involvement Predictive of Scleroderma Outcomes
Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).
Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).
A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID).
Read Article
Links:
Links:
At least some patients with inflammatory bowel disease (IBD) can safely use common drugs for musculoskeletal aches and pains, a large study of insurance claims data suggested, contradicting a widespread concern that these products can trigger IBD flares.
Read ArticleA retrospective target trial emulations has shown that low-dose aspirin (ASA) given with a giant cell arteritis (GCA) diagnosis is associated with a lower risk of major adverse cardiovascular events (MACE), but a higher risk of GI bleeding.
Read ArticleDr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
JAMA has published a current Clinical Guidelines Synopsis on the Management of Crohn Disease (CD) in Adults.
Read Article
Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.
Read ArticleYesterday the FDA issued a Drug Safety Communication alerting patients and health care professionals about postmarketing identification of serious (drug induced) liver injury, including fatal cases, associated with the use of avacopan (Tavneos) in patients with ANCA- associated vasculitis.
Read Article
In 2020, the ACR Recommendations on Reproductive Health notably avoided firm guidance on the use of JAK inhibitors (JAKi) during pregnancy stating, "There is no available evidence regarding use or safety of the new small- molecule agents, tofacitinib, baricitinib, and apremilast, during
Read Article
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com
Read Article
With their publication in June 2022 (1), the 3rd iteration of the Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for Psoriatic Arthritis (PsA) may have set a record or sorts.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.